More tools:Markets·Screener·Research·Chat

Arcadia Biosciences, Inc. (RKDA) Financial Statements

Arcadia Biosciences, Inc.
SIC 1311 · CRUDE PETROLEUM & NATURAL GAS
FIGI BBG001SP1Y87
XNAS · usd
0.47▼ 0.00 (-0.53%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value—
Trailing P/E—
Price / Sales
EV / Revenue—
EV / EBITDA—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt—
Trading Information
Previous Close0.47
Day's Range0.45 – 0.48
52-Week Range0.38 – 6.71
Volume71.8K
Avg Volume126.9K
Share Statistics
Shares Outstanding
Employees8
ExchangeXNAS
Listed2015-05-15
Share count as of August 6, 2026
Loading Income Statement…
Key questions about Arcadia Biosciences, Inc. (RKDA)
What is Arcadia Biosciences, Inc.'s Market Cap?
Arcadia Biosciences, Inc.'s Market Cap is $1.1M, based on as-reported figures from SEC (XBRL) filings.
What is Arcadia Biosciences, Inc.'s Price / Sales?
Arcadia Biosciences, Inc.'s Price / Sales is 0.2×, based on as-reported figures from SEC (XBRL) filings.
What is Arcadia Biosciences, Inc.'s Revenue (TTM)?
Arcadia Biosciences, Inc.'s Revenue (TTM) is $4.7M, based on as-reported figures from SEC (XBRL) filings.
What is Arcadia Biosciences, Inc.'s Net Income (TTM)?
Arcadia Biosciences, Inc.'s Net Income (TTM) is -$11.1M, based on as-reported figures from SEC (XBRL) filings.
What is Arcadia Biosciences, Inc.'s EBITDA?
Arcadia Biosciences, Inc.'s EBITDA is -$3.8M, based on as-reported figures from SEC (XBRL) filings.
What is Arcadia Biosciences, Inc.'s Diluted EPS (TTM)?
Arcadia Biosciences, Inc.'s Diluted EPS (TTM) is -4.62, based on as-reported figures from SEC (XBRL) filings.
What is Arcadia Biosciences, Inc.'s EBITDA Margin?
Arcadia Biosciences, Inc.'s EBITDA Margin is -79.9%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenues:
Total revenues
YoY growth-0.8%-8.3%-25.9%-15.3%
Operating expenses (income):
Cost of revenues
Research and development—
Change in fair value of contingent consideration
Selling, general and administrative
Total operating expenses
% of revenue134.4%170.8%252.6%188.5%
(Loss) Income from continuing operations
% of revenue-34.4%-70.8%-152.6%-88.5%
Interest income
Other (loss) income, net
Loss on January 2026 Inducement Offer——
Valuation loss on June 2026 PIPE———
Change in fair value of common stock warrant and option liabilities
Issuance and offering costs——
Net (loss) income from continuing operations
% of revenue-434.2%-398.6%-148.3%65.7%
Net loss per share attributable to common stockholders:
Basic
Diluted